CAMBRIDGE, U.K.—Isogenica Ltd. and Maverick Therapeutics, an MPM Capital portfolio company, have joined forces in a license agreement centered around Isogenica’s family of antibody libraries. Per the deal, Maverick has received a license to Isogenica’s llamdA VHH single-domain antibody libraries for the discovery, development and commercialization of therapeutic products derived from the libraries. In return, Isogenica stands to receive an upfront payment as well as annual license payments and, should antibodies be moved into development, additional commercial upfront and milestone payments. No specific financial details were disclosed. Isogenica’s libraries can be screened in a variety of formats, including phage and CIS-Display, a proprietary in-vitro display technology that maintains the libraries’ diversity through the discovery process.